Skip Navigation
Print This Page
Share this page: More

Dr. Chien-Fu Hung


Cancer vaccines, Gene therapies


Assistant Professor of Pathology


Ph.D. (Molecular Biology), University of Illinois


Postdoctoral Fellowship (Pharmacology), University of Pennsylvania
Postdoctoral Fellowship (Pathology), Johns Hopkins University

Research Summary

Cervical cancer is the second leading cause of death from cancer in women worldwide, while patients with ovarian cancer have a higher mortality rate than all other patients with gynecologic malignancies.

Dr. Hung’s research centers primarily on developing immmunotherapeutic, specifically vaccination, strategies for the prevention and treatment of cervical and ovarian cancers. This lab has developed several strategies to enhance immunologic responses against cancers. Some of these strategies involve targeting an antigen into dendritic cells, targeting an antigen into MHC class I and II processing pathways, enhancing intercellular spreading of antigen, and combining antigen-specific immunotherapy and antiangiogenesis.

Currently, our laboratory has developed an ascitogenic ovarian/peritoneal tumor model that can be used to investigate the interaction of the immune system with the establishment, progression and treatment of ovarian cancer in immunocompetent mice. Unlike models using human xenografts or human cell lines, which are limited to studies with immunocompromised mice, our model is capable of generating ascites and intraperitoneal tumor growth in immunocompetent C57BL/6 mice after intraperitoneal injection. We are presently investigating DNA vaccine strategies encoding ovarian tumor antigens identified by microarray and SAGE in this tumor model.


EM 5/06

Journal Citations

Best, S.R.; Peng, S.; Juang, C.M.; Hung, C.F.; Hannaman, D.; Saunders, J.R.; Wu, T.C.; Pai, S.I. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine. 2009 Sep 4;27(40):5450-5459.

Chang, C.L.; Ma, B.; Pang, X.; Wu, T.C.; Hung, C.F. Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer. Mol Ther. 2009 Aug;17(8):1365-1372.

Chuang, C.M.; Hoory, T.; Monie, A.; Wu, A.; Wang, M.C.; Hung, C.F. Enhancing therapeutic HPV DNA vaccine potency through depletion of CD4+CD25+ T regulatory cells. Vaccine. 2009 Jan 29;27(5):684-689.

Chuang, C.M.; Monie, A.; Wu, A.; Hung, C.F. Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects. J Biomed Sci. 2009;16:49.

Chuang, C.M.; Monie, A.; Wu, A.; Mao, C.P.; Hung, C.F. Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer. Hum Gene Ther. 2009 Apr;20(4):303-313.

Chuang, C.M.; Monie, A.; Wu, A.; Pai, S.I.; Hung, C.F. Combination of viral oncolysis and tumor-specific immunity to control established tumors. Clin Cancer Res. 2009 Jul 15;15(14):4581-4588.

Lu, D.; Hoory, T.; Monie, A.; Wu, A.; Wang, M.C.; Hung, C.F. Treatment with demethylating agent, 5-aza-2'-deoxycytidine enhances therapeutic HPV DNA vaccine potency. Vaccine. 2009 Jul 9;27(32):4363-4369.

Monie, A.; Tsen, S.W.; Hung, C.F.; Wu, T.C. Therapeutic HPV DNA vaccines. Expert Rev Vaccines. 2009 Sep;8(9):1221-1235.

Noh, K.H.; Kang, T.H.; Kim, J.H.; Pai, S.I.; Lin, K.Y.; Hung, C.F.; Wu, T.C.; Kim, T.W. Activation of Akt as a mechanism for tumor immune evasion. Mol Ther. 2009 Mar;17(3):439-447.

Rowley, J.; Monie, A.; Hung, C.F.; Wu, T.C. Expression of IL-15RA or an IL-15/IL-15RA fusion on CD8+ T cells modifies adoptively transferred T-cell function in cis. Eur J Immunol. 2009 Feb;39(2):491-506.

Tsen, S.W.; Wu, C.Y.; Meneshian, A.; Pai, S.I.; Hung, C.F.; Wu, T.C. Femtosecond laser treatment enhances DNA transfection efficiency in vivo. J Biomed Sci. 2009;16:36.

Tseng, C.W.; Trimble, C.; Zeng, Q.; Monie, A.; Alvarez, R.D.; Huh, W.K.; Hoory, T.; Wang, M.C.; Hung, C.F.; Wu, T.C. Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts. Cancer Immunol Immunother. 2009 May;58(5):737-748.

Chuang, C.M.; Monie, A.; Hung, C.F.; Wu, T.C. Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination. J Biomed Sci. 2010;17:32.

Kang, T.H.; Noh, K.H.; Kim, J.H.; Bae, H.C.; Lin, K.Y.; Monie, A.; Pai, S.I.; Hung, C.F.; Wu, T.C.; Kim, T.W. Ectopic expression of X-linked lymphocyte-regulated protein pM1 renders tumor cells resistant to antitumor immunity. Cancer Res. 2010 Apr 15;70(8):3062-3070.

Kim, D.; Hoory, T.; Monie, A.; Wu, A.; Hsueh, W.T.; Pai, S.I.; Hung, C.F. Delivery of chemotherapeutic agents using drug-loaded irradiated tumor cells to treat murine ovarian tumors. J Biomed Sci. 2010;17:61.

Kim, D.; Hung, C.F.; Wu, T.C.; Park, Y.M. DNA vaccine with alpha-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells. Vaccine. 2010 Oct 21;28(45):7297-7305.

Lin, K.; Doolan, K.; Hung, C.F.; Wu, T.C. Perspectives for preventive and therapeutic HPV vaccines. J Formos Med Assoc. 2010 Jan;109(1):4-24.

Lin, K.; Roosinovich, E.; Ma, B.; Hung, C.F.; Wu, T.C. Therapeutic HPV DNA vaccines. Immunol Res. 2010 Jul;47(1-3):86-112.

Lyford-Pike, S.; Westra, W.H.; Loyo, M.; Peng, S.; Hung, C.F.; Wu, A.A.; Flint, P.W.; Tunkel, D.E.; Saunders, J.R.; Pai, S.I. Differential expression of epidermal growth factor receptor in juvenile and adult-onset recurrent respiratory papillomatosis. Histopathology. 2010 Nov;57(5):768-770.

Mao, C.P.; Hung, C.F.; Kang, T.H.; He, L.; Tsai, Y.C.; Wu, C.Y.; Wu, T.C. Combined administration with DNA encoding vesicular stomatitis virus G protein enhances DNA vaccine potency. J Virol. 2010 Mar;84(5):2331-2339.

Peng, S.; Best, S.R.; Hung, C.F.; Loyo, M.; Lyford-Pike, S.; Flint, P.W.; Tunkel, D.E.; Saunders, J.R.; Wu, T.C.; Pai, S.I. Characterization of human papillomavirus type 11-specific immune responses in a preclinical model. Laryngoscope. 2010 Mar;120(3):504-510.

Su, J.H.; Wu, A.; Scotney, E.; Ma, B.; Monie, A.; Hung, C.F.; Wu, T.C. Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs. 2010 Apr 1;24(2):109-129.

Wu, C.Y.; Monie, A.; Pang, X.; Hung, C.F.; Wu, T.C. Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation. J Biomed Sci. 2010;17:88.

Zhang, Y.Q.; Tsai, Y.C.; Monie, A.; Hung, C.F.; Wu, T.C. Carrageenan as an adjuvant to enhance peptide-based vaccine potency. Vaccine. 2010 Jul 19;28(32):5212-5219.

Zhang, Y.Q.; Tsai, Y.C.; Monie, A.; Wu, T.C.; Hung, C.F. Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy. Mol Ther. 2010 Apr;18(4):692-699.

Kang, T.H.; Monie, A.; Wu, L.S.; Pang, X.; Hung, C.F.; Wu, T.C. Enhancement of protein vaccine potency by in vivo electroporation mediated intramuscular injection. Vaccine. 2011 Jan 29;29(5):1082-1089.


Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424



© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer